ATE483027T1 - Rekombinante n-glykosylierte proteine aus prokaryontischen zellen - Google Patents

Rekombinante n-glykosylierte proteine aus prokaryontischen zellen

Info

Publication number
ATE483027T1
ATE483027T1 AT06753552T AT06753552T ATE483027T1 AT E483027 T1 ATE483027 T1 AT E483027T1 AT 06753552 T AT06753552 T AT 06753552T AT 06753552 T AT06753552 T AT 06753552T AT E483027 T1 ATE483027 T1 AT E483027T1
Authority
AT
Austria
Prior art keywords
recombinant
cells
prokaryontic
proteins
glycosylated proteins
Prior art date
Application number
AT06753552T
Other languages
German (de)
English (en)
Inventor
Markus Aebi
Michael Kowarik
Umesh Ahuja
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich filed Critical Eth Zuerich
Application granted granted Critical
Publication of ATE483027T1 publication Critical patent/ATE483027T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25Shigella (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/01Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06753552T 2005-05-11 2006-05-10 Rekombinante n-glykosylierte proteine aus prokaryontischen zellen ATE483027T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05010276 2005-05-11
PCT/EP2006/004397 WO2006119987A2 (en) 2005-05-11 2006-05-10 Recombinant n-glycosylated proteins from procaryotic cells

Publications (1)

Publication Number Publication Date
ATE483027T1 true ATE483027T1 (de) 2010-10-15

Family

ID=37396912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06753552T ATE483027T1 (de) 2005-05-11 2006-05-10 Rekombinante n-glykosylierte proteine aus prokaryontischen zellen

Country Status (19)

Country Link
US (3) US8753864B2 (OSRAM)
EP (3) EP1888761B1 (OSRAM)
JP (3) JP5356807B2 (OSRAM)
KR (2) KR101408653B1 (OSRAM)
CN (2) CN101360831B (OSRAM)
AT (1) ATE483027T1 (OSRAM)
AU (1) AU2006245969B8 (OSRAM)
CA (1) CA2607595C (OSRAM)
CY (1) CY1116285T1 (OSRAM)
DE (1) DE602006017207D1 (OSRAM)
DK (2) DK1888761T3 (OSRAM)
ES (3) ES2703061T3 (OSRAM)
HK (1) HK1205193A1 (OSRAM)
HR (1) HRP20150312T1 (OSRAM)
IL (2) IL187293A (OSRAM)
PL (1) PL2311972T3 (OSRAM)
PT (2) PT2311972E (OSRAM)
SI (1) SI2311972T1 (OSRAM)
WO (1) WO2006119987A2 (OSRAM)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
ATE317897T1 (de) 2002-03-07 2006-03-15 Eidgenoess Tech Hochschule System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2552892C (en) 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
US8092788B2 (en) * 2004-03-03 2012-01-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
SG160357A1 (en) 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー/エス グリコペグ化第ix因子
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
JP2010523582A (ja) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト グリコpeg化g−csfを用いた治療方法
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
JP5667880B2 (ja) 2008-01-03 2015-02-12 コーネル リサーチ ファンデーション インコーポレイテッド 原核生物におけるグリコシル化されたタンパク質の発現方法
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
WO2009104074A2 (en) * 2008-02-20 2009-08-27 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
RU2573587C2 (ru) 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
US9309493B2 (en) * 2009-03-27 2016-04-12 Eidgenoessische Technische Hochschule Zurich Salmonella enterica presenting C. jejuni N-glycan or derivatives thereof
ES2660227T3 (es) * 2009-11-19 2018-03-21 Glaxosmithkline Biologicals S.A. Sistema biosintético que produce polisacáridos inmunogénicos en células procariotas
PT2545081E (pt) 2010-02-11 2015-05-18 Univ Alberta Compostos de glicano ligados por n
CN103079591B (zh) * 2010-05-06 2017-07-28 格林考瓦因有限公司 荚膜革兰氏阳性细菌生物缀合物疫苗
US20130266604A1 (en) * 2010-09-03 2013-10-10 The Governors of the University of Alberta a non-profit educational institution Peptide containing multiple n-linked glycosylation sequons
AU2012306345A1 (en) * 2011-09-06 2014-03-20 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
EA201590705A1 (ru) 2012-11-07 2016-05-31 Гликоваксин Аг ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
PL2945651T3 (pl) 2013-01-17 2018-08-31 Arsanis Biosciences Gmbh Przeciwciało swoiste wobec E.coli MDR
EP2946010B1 (en) 2013-01-18 2018-08-29 London School of Hygiene and Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
CN105228984B (zh) 2013-03-15 2018-03-23 爱西里斯药物技术有限公司 硝羟喹啉碱加成盐及其用途
BR112015025288B1 (pt) * 2013-04-05 2023-02-23 The Governors Of The University Of Alberta Composição de vacina para uso na vacinação de galinhas contra campylobacter
CN106062203B (zh) * 2013-10-11 2020-08-07 葛兰素史密丝克莱恩生物有限公司 宿主细胞修饰的方法
SI3110441T1 (sl) 2014-02-24 2024-07-31 Glaxosmithkline Biologicals S.A. Novi polisaharidi in njihova uporaba
CA2945542C (en) 2014-04-17 2024-03-05 Glycovaxyn Ag Modified host cells and uses thereof
MX378792B (es) 2014-08-08 2025-03-10 Glaxosmithkline Biologicals Sa Células hospederas modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados.
ES2907211T3 (es) * 2014-12-30 2022-04-22 Glaxosmithkline Biologicals Sa Composiciones y métodos para la glicosilación de proteínas
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) * 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
WO2017117539A1 (en) 2015-12-30 2017-07-06 Northwestern University Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US10829795B2 (en) 2016-07-14 2020-11-10 Northwestern University Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
EP3573654A4 (en) * 2017-01-27 2020-11-25 University of Florida Research Foundation, Incorporated FOOD SAFETY VACCINE TO CONTROL SALMONELLA ENTERICA AND REDUCE CAMPYLOBACTER IN POULTRY
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) * 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11725224B2 (en) 2018-04-16 2023-08-15 Northwestern University Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
US12098433B2 (en) 2018-08-03 2024-09-24 Northwestern University On demand, portable, cell-free molecular sensing platform
EP3894431A2 (en) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modified carrier proteins for o-linked glycosylation
KR20210116512A (ko) 2019-01-11 2021-09-27 노쓰웨스턴유니버시티 원핵생물 세포 용해물에서의 생체접합체 백신 합성
US12325884B2 (en) 2019-03-04 2025-06-10 Northwestern University Riboswitch-based fluoride sensing in cell-free extract
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
US11446370B2 (en) 2019-03-18 2022-09-20 Janssen Pharmaceuticals, Inc. Bioconjugates of E. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) * 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US12226410B2 (en) 2019-10-18 2025-02-18 Northwestern University Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
IL294445B2 (en) 2020-01-16 2023-10-01 Janssen Pharmaceuticals Inc FIMH mutant, its preparations and their use
EP4168040A1 (en) 2020-06-18 2023-04-26 GlaxoSmithKline Biologicals S.A. Shigella-tetravalent (shigella4v) bioconjugate
EP4171624A1 (en) 2020-06-25 2023-05-03 GlaxoSmithKline Biologicals S.A. Modified exotoxin a proteins
BR112023004819A2 (pt) 2020-09-17 2023-04-18 Janssen Pharmaceuticals Inc Composições de vacinas multivalentes e seus usos
KR20250007029A (ko) 2021-01-12 2025-01-13 얀센 파마슈티칼즈, 인코포레이티드 FimH 돌연변이체, 이를 포함하는 조성물 및 이의 용도
UY39710A (es) 2021-04-01 2022-09-30 Janssen Pharmaceuticals Inc Producción de bioconjugados de o18 de e. coli
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
WO2025032535A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025032534A2 (en) 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
AU6663294A (en) 1993-05-14 1994-12-12 Upjohn Company, The Cloned dna encoding a udp-galnac:polypeptide,n-acetylgalactos aminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
EP1399538A4 (en) 1999-03-02 2004-03-24 Human Genome Sciences Inc TECHOLOGICAL MANIPULATION OF INTRACELLULAR SIALIZATION PATHS
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
JP2004528001A (ja) 2000-05-12 2004-09-16 ネオーズ テクノロジーズ, インコーポレイテッド インビトロにおけるフコシル化組換えグリコペプチド
EP1294910B1 (en) 2000-06-30 2008-11-19 VIB vzw Protein glycosylation modification in pichia pastoris
DE10113573A1 (de) * 2001-03-20 2002-02-28 Messer Griesheim Gmbh Verfahren zum Regenerieren von Schwefelsäure aus schwefelhaltigen Reststoffen
ATE317897T1 (de) 2002-03-07 2006-03-15 Eidgenoess Tech Hochschule System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
KR20100119905A (ko) 2002-03-07 2010-11-11 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
EP1527080B1 (en) * 2002-08-01 2012-06-20 National Research Council Of Canada Campylobacter glycans and glycopeptides

Also Published As

Publication number Publication date
KR20080048990A (ko) 2008-06-03
KR20140019482A (ko) 2014-02-14
JP2008539743A (ja) 2008-11-20
KR101408653B1 (ko) 2014-06-17
CA2607595C (en) 2018-11-27
PT2311972E (pt) 2015-05-13
CN101360831B (zh) 2013-07-10
AU2006245969B2 (en) 2011-06-02
DK2311972T3 (en) 2015-04-27
EP1888761A2 (en) 2008-02-20
IL226857A (en) 2017-08-31
CN103396478B (zh) 2016-09-28
ES2353814T3 (es) 2011-03-07
WO2006119987A2 (en) 2006-11-16
HK1113588A1 (en) 2008-10-10
JP2014042533A (ja) 2014-03-13
US8753864B2 (en) 2014-06-17
ES2703061T3 (es) 2019-03-06
AU2006245969B8 (en) 2011-08-25
IL226857A0 (en) 2013-07-31
PT1888761E (pt) 2011-01-03
DK1888761T3 (da) 2010-11-01
CN101360831A (zh) 2009-02-04
HRP20150312T1 (hr) 2015-07-31
KR101524636B1 (ko) 2015-06-03
CN103396478A (zh) 2013-11-20
EP2311972A1 (en) 2011-04-20
PL2311972T3 (pl) 2015-08-31
EP2853600B1 (en) 2018-09-19
CA2607595A1 (en) 2006-11-16
US9551019B2 (en) 2017-01-24
EP2311972B1 (en) 2015-01-21
ES2535084T3 (es) 2015-05-05
JP5687637B2 (ja) 2015-03-18
DE602006017207D1 (de) 2010-11-11
IL187293A0 (en) 2008-04-13
IL187293A (en) 2013-06-27
JP2012100678A (ja) 2012-05-31
AU2006245969A1 (en) 2006-11-16
US20140323700A1 (en) 2014-10-30
EP2853600A1 (en) 2015-04-01
JP5827303B2 (ja) 2015-12-02
HK1205193A1 (en) 2015-12-11
SI2311972T1 (sl) 2015-08-31
US20160326563A1 (en) 2016-11-10
EP1888761B1 (en) 2010-09-29
JP5356807B2 (ja) 2013-12-04
CY1116285T1 (el) 2017-02-08
WO2006119987A3 (en) 2007-03-08
US20100062484A1 (en) 2010-03-11
HK1156983A1 (en) 2016-11-25

Similar Documents

Publication Publication Date Title
ATE483027T1 (de) Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
TNSN08064A1 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
WO2007146038A3 (en) Albumin fusion proteins
WO2005077042A3 (en) Albumin fusion proteins
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
ES2379283T3 (es) Proteínas de unión a albúmina sérica
MX336807B (es) Composiciones y metodos para producir una composicion.
BRPI0507623A (pt) peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
BRPI0606687A2 (pt) composições nutracêuticas
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
ATE533837T1 (de) Microginin-produzierende proteine und nukleinsäuren, einen microginin gen-cluster kodierend, sowie methoden zur herstellung von microgininen
WO2006017355A3 (en) Improved aprotinin variants
WO2006047728A3 (en) Bmp gene and fusion protein
TW200734350A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
TW200724679A (en) Treatment of disease using an improved regulated expression system
TW200700076A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1888761

Country of ref document: EP